A detailed history of Golden State Equity Partners transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Golden State Equity Partners holds 12,097 shares of SGMO stock, worth $22,742. This represents 0.01% of its overall portfolio holdings.

Number of Shares
12,097
Previous 266,484 95.46%
Holding current value
$22,742
Previous $229,000 95.63%
% of portfolio
0.01%
Previous 0.05%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$0.32 - $1.1 $81,403 - $279,825
-254,387 Reduced 95.46%
12,097 $10,000
Q3 2024

Oct 25, 2024

BUY
$0.32 - $1.1 $22,197 - $76,304
69,368 Added 35.19%
266,484 $229,000
Q2 2024

Jul 29, 2024

SELL
$0.36 - $0.65 $1,479 - $2,670
-4,109 Reduced 2.04%
197,116 $70,000
Q4 2023

Feb 02, 2024

BUY
$0.3 - $0.63 $10,488 - $22,024
34,960 Added 21.03%
201,225 $108,000
Q3 2023

Oct 20, 2023

BUY
$0.58 - $1.47 $17,690 - $44,835
30,500 Added 22.47%
166,265 $99,000
Q1 2023

Jun 01, 2023

SELL
$1.66 - $3.67 $30,867 - $68,243
-18,595 Reduced 12.05%
135,765 $239 Million
Q1 2022

May 18, 2022

BUY
$5.23 - $7.82 $145,142 - $217,020
27,752 Added 21.92%
154,360 $897,000
Q1 2022

May 16, 2022

SELL
$5.23 - $7.82 $89,746 - $134,191
-17,160 Reduced 11.94%
126,608 $1.59 Million
Q4 2021

Feb 11, 2022

BUY
$7.29 - $10.97 $118,119 - $177,746
16,203 Added 12.7%
143,768 $1.08 Million
Q3 2021

Nov 15, 2021

BUY
$9.01 - $12.01 $2,315 - $3,086
257 Added 0.2%
127,565 $1.15 Million
Q2 2021

Aug 12, 2021

BUY
$10.17 - $12.64 $7,119 - $8,848
700 Added 0.55%
127,308 $1.52 Million
Q1 2021

May 13, 2021

BUY
$10.88 - $17.05 $30,366 - $47,586
2,791 Added 2.25%
126,608 $1.59 Million
Q4 2020

Feb 08, 2021

BUY
$9.23 - $18.18 $1.14 Million - $2.25 Million
123,817 New
123,817 $1.93 Million

Others Institutions Holding SGMO

About SANGAMO THERAPEUTICS, INC


  • Ticker SGMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 156,552,992
  • Market Cap $294M
  • Description
  • Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...
More about SGMO
Track This Portfolio

Track Golden State Equity Partners Portfolio

Follow Golden State Equity Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Golden State Equity Partners, based on Form 13F filings with the SEC.

News

Stay updated on Golden State Equity Partners with notifications on news.